ワシントンにおける骨髄異形成症候群の臨床試験
ワシントン内の拠点で、骨髄異形成症候群に関する21件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06577441A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Fred Hutchinson Cancer Center, Seattle
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- University of Washington, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT05320198CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT04375631Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT04282187Collection of Tissue Samples for Cancer Research
- Fred Hutchinson, Seattle
被験者募集中観察研究
2 Months · 全性別 · 2026/09/16更新 · NCT00900198The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- 他1件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06529731Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
6 Months – 65 Years · 全性別 · 2026/07/22更新 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/20更新 · NCT07046078Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相健康なボランティア歓迎
6 Months · 全性別 · 2026/05/29更新 · NCT04195633HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第1相
80歳以下 · 全性別 · 2026/05/18更新 · NCT03326921Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第1/2相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/05/15更新 · NCT06928662A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Seattle Cancer Care Alliance, Seattle
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT05732103Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
1歳〜60歳 · 全性別 · 2026/03/12更新 · NCT03970096HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第2相
3 Months · 全性別 · 2025/11/12更新 · NCT02143830SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/24更新 · NCT06501196Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/15更新 · NCT06462365ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。